Control

a. Constant release of prostaglandin at approximately 0.3mg per hour for up to 24 hours¹

b. The product can be removed quickly and easily¹

Acceptability

a. Women’s experience of dinoprostone insert in situ – 88% were unaware of its presence intravaginally whilst 9% who were aware felt no discomfort⁵

b. High degree of acceptability by both women and clinicians⁴

Efficacy

Efficacy of Dinoprostone is similar to other prostaglandin E2 (PGE2) preparations⁶

Safety

a. Well tolerated in achieving cervical ripening and labour in both nulliparous and multiparous women⁴

b. 3-year follow up: no adverse consequences on child health or development⁷

c. Can be used with caution in women presenting with pre-labour rupture of the membrane (PROM) (should be removed if membranes rupture while dinoprostone is in place). Since the release of dinoprostone from the insert can be affected by the presence of amniotic fluid, special attention should be given to uterine activity and foetal condition¹

d. The most common adverse events (AEs) (≥ 1/100 to < 1/10) reported from clinical trials were foetal heart rate disorder (6.9%), uterine contractions abnormal (6.2%) and abnormal labour affecting foetus (2.6%). Other common AEs were uterine tachysystole, uterine hyperstimulation, uterine hypertonus amd meconium in amniotic fluid.¹